|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
antineoplastic agent
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01FG12
|
|
gptkbp:brand
|
gptkb:Enhertu
|
|
gptkbp:CASNumber
|
gptkb:2228327-56-2
|
|
gptkbp:coDeveloper
|
gptkb:AstraZeneca
|
|
gptkbp:contains
|
gptkb:trastuzumab_(antibody)
deruxtecan (payload)
|
|
gptkbp:developer
|
gptkb:Daiichi_Sankyo
|
|
gptkbp:form
|
lyophilized powder for solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Trastuzumab deruxtecan
|
|
gptkbp:indication
|
gptkb:non-small_cell_lung_cancer
gptkb:gastric_or_gastroesophageal_junction_adenocarcinoma
metastatic breast cancer
unresectable breast cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:ERBB2
monoclonal antibody-drug conjugate
|
|
gptkbp:mechanismOfAction
|
HER2-targeted antibody linked to topoisomerase I inhibitor
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
fatigue
neutropenia
interstitial lung disease
|
|
gptkbp:target
|
gptkb:HER2_protein
|
|
gptkbp:UNII
|
6Y7T7T8A5B
|
|
gptkbp:usedFor
|
gptkb:HER2-positive_breast_cancer
gptkb:HER2-mutant_non-small_cell_lung_cancer
HER2-positive gastric cancer
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|